arginyl- phenylalanyl- valyl- prolyl- aspartyl- glycyl- asparagyl- arginyl- isoleucine

elpamotide is a vaccine consisting of VEGFR2-169 peptide

Also Known As:

Arg-Phe-Val-Pro-Asp-Gly-Asn-Arg-Ile; RFVPDGNRI; VEGFR2-169 peptide; elpamotide

Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - Receptor Protein-Tyrosine Kinases: 5999
        Vascular Endothelial Growth Factor Receptors: 3385
        Vascular Endothelial Growth Factor Receptor-2: 2196
        arginyl-phenylalanyl-valyl-prolyl-aspartyl-glycyl-asparagyl-arginyl-isoleucine: 4
      - Peptide Receptors: 1159
        Growth Factor Receptors: 2663
        Vascular Endothelial Growth Factor Receptors: 3385
        Vascular Endothelial Growth Factor Receptor-2: 2196
        arginyl-phenylalanyl-valyl-prolyl-aspartyl-glycyl-asparagyl-arginyl-isoleucine: 4
  - Intracellular Signaling Peptides and Proteins: 32
    - Protein-Tyrosine Kinases: 7697
      - Receptor Protein-Tyrosine Kinases: 5999
        Vascular Endothelial Growth Factor Receptors: 3385
        Vascular Endothelial Growth Factor Receptor-2: 2196
        arginyl-phenylalanyl-valyl-prolyl-aspartyl-glycyl-asparagyl-arginyl-isoleucine: 4
- Peptides: 82426
  - Peptide Fragments: 373
    - arginyl-phenylalanyl-valyl-prolyl-aspartyl-glycyl-asparagyl-arginyl-isoleucine: 4
Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Transferases: 6589
    - Phosphotransferases: 42769
      - Phosphotransferases (Alcohol Group Acceptor)
        Protein Kinases: 9677
        Protein-Tyrosine Kinases: 7697
        Receptor Protein-Tyrosine Kinases: 5999
        Vascular Endothelial Growth Factor Receptors: 3385
        Vascular Endothelial Growth Factor Receptor-2: 2196
        arginyl-phenylalanyl-valyl-prolyl-aspartyl-glycyl-asparagyl-arginyl-isoleucine: 4

Experts

1.	Miyazawa, Motoki: 2 articles (07/2015 - 11/2011)
2.	Nishio, Kazuto: 2 articles (07/2015 - 12/2012)
3.	Tsunoda, Takuya: 2 articles (07/2015 - 12/2012)
4.	Yamaue, Hiroki: 2 articles (07/2015 - 11/2011)
5.	Boku, Narikazu: 1 article (07/2015)
6.	Fukutomi, Akira: 1 article (07/2015)
7.	Furukawa, Masayuki: 1 article (07/2015)
8.	Ikeda, Masafumi: 1 article (07/2015)
9.	Ishii, Hiroshi: 1 article (07/2015)
10.	Maguchi, Hiroyuki: 1 article (07/2015)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2012 - "Ten HLA-A*24:02-positive patients with advanced refractory solid tumors received elpamotide s.c. " 11/01/2011 - "The phase I clinical trial using VEGFR2-169 peptide that successfully induced specific CTLs in cancer patients, combined with gemcitabine (GEM), was conducted for patients with advanced pancreatic cancer. " 12/01/2012 - "Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors." 07/01/2015 - "Vascular endothelial growth factor receptor 2 is an essential target for tumor angiogenesis, and we have conducted a phase I clinical trial using gemcitabine and vascular endothelial growth factor receptor 2 peptide (elpamotide). "
2.	Pancreatic Neoplasms (Pancreatic Cancer) 07/01/2015 - "Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study." 11/01/2011 - "The phase I clinical trial using VEGFR2-169 peptide that successfully induced specific CTLs in cancer patients, combined with gemcitabine (GEM), was conducted for patients with advanced pancreatic cancer. "
3.	Biliary Tract Neoplasms (Biliary Tract Cancer) 04/01/2015 - "Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer." 04/01/2015 - "Given the high expression of VEGFR-2 in biliary tract cancer, combination chemoimmunotherapy with elpamotide and gemcitabine holds promise as a new therapy. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
2.	Gemcitabine
3.	Protein Subunit Vaccines
4.	Peptides (Polypeptides)
5.	HLA-A*24:02 antigen

Related Therapies and Procedures

1.	Therapeutics